TABLE 4.

In vivo efficacies of murepavadin against P. aeruginosa isolates in the neutropenic lung infection models

P. aeruginosa isolate or data measure	MIC (mg/liter)	Bacterial burden at start of therapy (log10 CFU/lung)	Bacterial burden with 24 h growth in untreated control animals (log10 CFU/lung)	No. of CFU/lung for maximum kill at 24 h from 0 h (Δlog10 CFU/lung)	Values resulting in static effect			Values resulting in 1-log reductiona
					fAUC	fAUC/MIC	ELF AUC/MIC	fAUC	fAUC/MIC	ELF AUC/MIC
ATCC 27853	0.125	5.62	2.94	−3.98	2.03	16.25	20.15	3.09	24.74	30.67
ATCC BAA2113	0.125	5.48	2.3	−2.03	0.76	6.10	7.57	4.68	37.43	46.41
NCTC 13437	0.25	5.25	2.97	−2.98	2.24	8.94	11.09	3.63	14.54	18.03
5	1	6.39	3.42	−0.25	25.72	25.72	31.89	NR	NR	NR
9	0.25	5.72	3.65	−1.75	7.77	31.07	38.52	12.89	51.56	63.93
6	0.5	4.58	3.42	−2.93	2.51	5.03	6.23	5.01	10.03	12.43
11	0.5	4.48	1.64	−2.78	3.63	7.27	9.01	7.77	15.53	19.26
12	0.25	4.56	3.21	−1.97	9.33	37.33	46.29	14.80	59.20	73.40
15	0.25	6.33	2.05	−1.98	6.31	25.26	31.32	6.61	26.45	32.80
16	0.25	4.89	2.42	−3.25	0.84	3.34	4.15	1.15	4.60	5.71
18	0.25	6.06	2.81	−3.05	6.17	24.67	30.59	11.23	44.90	55.68
19	0.25	5.87	3.15	−1.76	21.89	87.55	108.57	23.30	93.18	115.55
21	0.25	4.99	2.94	−2.44	6.92	27.69	34.33	7.08	28.31	35.10
22	0.25	4.93	3.45	−1.15	13.50	53.99	66.95	20.91	83.65	103.73
X11045	0.25	4.99	1.32	−1.95	14.13	56.54	70.10	15.95	63.81	79.13
Geometric mean		5.31	2.68	−2.00	5.20	18.98	23.53	7.52	30.06	37.28
Mean		5.34	2.78	−2.28	8.25	27.78	34.45	9.86	39.85	49.42
Median		5.25	2.94	−2.03	6.31	25.26	31.32	7.42	32.87	40.76
SD		0.64	0.69	0.92	7.58	23.46	29.08	6.84	27.44	34.02

^aNR, not reported.